Background The role of B-cell remains an enigma in the pathogenesis of ankylosing spondylitis （AS）. This study aimed to investigate the distributions of B-cells and subsets in peripheral blood of AS patients and obs...Background The role of B-cell remains an enigma in the pathogenesis of ankylosing spondylitis （AS）. This study aimed to investigate the distributions of B-cells and subsets in peripheral blood of AS patients and observe their changes in etanercept-treated AS patents. Methods We detected the proportions of CD19^＋ B-cell, naive B-cell （CD19^＋CD27）, memory B-cell （CD19^＋CD27dim） and plasmablast （CD19^＋CD27high） in peripheral blood of 66 patients with AS （39 at active stage, 27 at stable stage; 35 patients with peripheral joint involvement, 31 patients with axial involvement alone）, 30 patients with rheumatoid arthritis （RA） and 30 healthy volunteers using flow cytometry. And then we observed the changes of the above indexes of 39 active AS patients treated with etanercept in a randomized, double-blind, placebo-controlled trial. Results （1） Percentages of CD19^＋ B-cells in active or peripheral joint involvement AS patients increased more obviously than those in stable or axial involvement alone AS patients （both P=0.001）, and percentage of CD19^＋CD27high B-cells in AS patients with peripheral joint involvement was significantly higher than that in cases with axial involvement alone or healthy volunteers （P=0.005 and 0.006, respectively）; （2） The percentage of CD19~ B-cells in AS patients was positively correlated with Bath Ankylosing Spondylitis Disease Activity Index （BASDAI） scores, Patient＇s Global Assessment （PGA） scores, total back pain scores and nocturnal back pain scores （r=0.270, 0.255, 0.251 and 0.266, P=-0.029, 0.039, 0.042 and 0.031, respectively）; （3） At week 6 and week 12, there were no statistical differences of the percentages of B-cells and subsets between etanercept group and placebo group of AS patients （P 〉0.05）; the percentage of CD19^＋ B-cells in etanercept group was higher than that in healthy volunteers at week 12 （t=3.320, P=0.003）. Conclusions Misbalance is present in B-cells and some subsets in peripheral bloo展开更多
目的确定中国人血清游离轻链(sFLC)的正常值,评价 sFLC 在多发性骨髓瘤(MM)患者的诊断、疗效判断中的临床意义。方法自动免疫比浊法检测63例健康人 sFLC 水平,确定其正常参考区间。采用同样方法检测72例 MM 患者不同疾病阶段的 sFLC 水...目的确定中国人血清游离轻链(sFLC)的正常值,评价 sFLC 在多发性骨髓瘤(MM)患者的诊断、疗效判断中的临床意义。方法自动免疫比浊法检测63例健康人 sFLC 水平,确定其正常参考区间。采用同样方法检测72例 MM 患者不同疾病阶段的 sFLC 水平,通过与传统的 M 蛋白检测方法的比较来评价 sFLC 的临床意义。结果 (1)健康人 sFLC-κ、sFLC-λ的95%参考区间分别为(9～29)mg/L、(15～34)mg/L,sFLC-κ/λ比值的中位值为0.59,100%参考区间为0.27～2.49。(2)初治 MM 患者中,κ增高的 MM(κ-MM)患者的 sFLC-κ、sFLC-λ的95%参考区间分别为(53～14 100)mg/L、(0～97)mg/L,sFLC-κ/λ比值中位值为10.27;λ增高的MM(λ-MM)患者的sFLC-κ、sFLC-λ95%参考区间分别为(9～117)mg/L、(205～6875)mg/L,sFLCκ/λ比值中位值是0.005。MM患者 sFLC-κ、sFLC-λ的95%参考区间与健康人间无交叉重叠。96.4%(26/27)初治 MM 患者的sFLCκ/λ比值异常。(3)健康人 sFLC-κ、sFLC-λ均与年龄呈正相关(P 值分别为0.031、0.01),而sFLCκ/λ比值与年龄无相关性(P=0.861)。初治 MM 患者年龄与 sFLC-κ、sFLC-λ浓度及 sFLCκ/λ比值间均无相关性(P 分别为0.287、0.408、0.471)。(4)对于初治患者,检测κ克隆时比浊法与免疫固定法的敏感性和特异性分别是100% vs 73.7%和100% vs 44.4%;检测λ克隆时比浊法与 IFE 法的敏感性和特异性分别是100% vs 68.8%和100% vs 58.3%。对于治疗后达完全缓解的 MM 患者比浊法仍可以检测到单克隆 M 蛋白的存在。结论首次获得了一个中国人 sFLC-κ、sFLC-λ及 sFLCκ/λ的正常参考区间。自动免疫比浊法检测 sFLC 可以提高 MM 患者的初诊时的阳性率和疗效判断准确率。展开更多
目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,...目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,SYFPEITHI和NetCTL方法预测分析其HLA-A*0201限制性CTL表位,运用NetCTL方法对HLA-A的其他等位基因和HLA-B限制性CTL表位进行预测分析.结果:HCCR蛋白的二级结构主要由α-螺旋结构组成,B细胞优势表位位于N端第41～53,216～228,310～325和355～360区段;预测得到5个HLA-A*0201限制性CTL优势表位分别为YLVFLLMYL(152～160),YLFPRQLLI(159～167),LLLHNVVLL(343～351),CLFLGIISI(138～146)和SIPPFA-NYL(145～153),HCCR蛋白HLA-A,B限制CTL表位主要位于胞外区.结论:应用多参数预测HCCR蛋白B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位,为进一步实验鉴定其表位进而制备单克隆抗体和基于HCCR抗原的肿瘤免疫学治疗奠定了基础.展开更多
Background:B cells represent a crucial component of adaptive immunity that ensures long-term protection from infection by generating pathogen-specific immunoglobulins.Exercise alters B cell counts and immunoglobulin l...Background:B cells represent a crucial component of adaptive immunity that ensures long-term protection from infection by generating pathogen-specific immunoglobulins.Exercise alters B cell counts and immunoglobulin levels,but evidence-based conclusions on potential benefits for adaptive immunity are lacking.This systematic review assessed current literatures on the impact of acute exercise and exercise training on B cells,immunoglobulins,and markers of secretory immunity in human biofluids.Methods:According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)guidelines,MEDLINE,Web of Science,and Embase were searched on March 8,2023.Non-randomized controlled trials and crossover trials investigating the impact of acute exercise or exercise training on B cell counts and proportions,immunoglobulin levels,salivary flow rate,or secretory immunoglobulin A secretion rate were included.Quality and reporting of exercise training studies were assessed using the Tool for the Assessment of Study Quality and reporting in Exercise.Study characteristics,outcome measures,and statistically significant changes were summarized tabularly.Results:Of the 67 eligible studies,22 applied acute exercise and 45 applied exercise training.All included outcomes revealed significant alterations over time in acute exercise and exercise training context,but only a few investigations showed significant differences compared to control conditions.Secretory and plasma immunoglobulin A levels were most consistently increased in response to exercise training.Conclusion:B cell-related outcomes are altered by acute exercise and exercise training,but evidence-based conclusions cannot be drawn with high confidence due to the large heterogeneity in populations and exercise modalities.Well-designed trials with large sample sizes are needed to clarify how exercise shapes B cell-related immunity.展开更多
基金This study was supported by the grants from the National Natural Science Foundation of China （No. 30325019, 30571735 and 30471611）, Ministry of Health Key Clinical Project and Science Foundation of Guangdong Province of China （No. 2002Z3-E4021 and 2005A30801005）.
文摘Background The role of B-cell remains an enigma in the pathogenesis of ankylosing spondylitis （AS）. This study aimed to investigate the distributions of B-cells and subsets in peripheral blood of AS patients and observe their changes in etanercept-treated AS patents. Methods We detected the proportions of CD19^＋ B-cell, naive B-cell （CD19^＋CD27）, memory B-cell （CD19^＋CD27dim） and plasmablast （CD19^＋CD27high） in peripheral blood of 66 patients with AS （39 at active stage, 27 at stable stage; 35 patients with peripheral joint involvement, 31 patients with axial involvement alone）, 30 patients with rheumatoid arthritis （RA） and 30 healthy volunteers using flow cytometry. And then we observed the changes of the above indexes of 39 active AS patients treated with etanercept in a randomized, double-blind, placebo-controlled trial. Results （1） Percentages of CD19^＋ B-cells in active or peripheral joint involvement AS patients increased more obviously than those in stable or axial involvement alone AS patients （both P=0.001）, and percentage of CD19^＋CD27high B-cells in AS patients with peripheral joint involvement was significantly higher than that in cases with axial involvement alone or healthy volunteers （P=0.005 and 0.006, respectively）; （2） The percentage of CD19~ B-cells in AS patients was positively correlated with Bath Ankylosing Spondylitis Disease Activity Index （BASDAI） scores, Patient＇s Global Assessment （PGA） scores, total back pain scores and nocturnal back pain scores （r=0.270, 0.255, 0.251 and 0.266, P=-0.029, 0.039, 0.042 and 0.031, respectively）; （3） At week 6 and week 12, there were no statistical differences of the percentages of B-cells and subsets between etanercept group and placebo group of AS patients （P 〉0.05）; the percentage of CD19^＋ B-cells in etanercept group was higher than that in healthy volunteers at week 12 （t=3.320, P=0.003）. Conclusions Misbalance is present in B-cells and some subsets in peripheral bloo
文摘目的确定中国人血清游离轻链(sFLC)的正常值,评价 sFLC 在多发性骨髓瘤(MM)患者的诊断、疗效判断中的临床意义。方法自动免疫比浊法检测63例健康人 sFLC 水平,确定其正常参考区间。采用同样方法检测72例 MM 患者不同疾病阶段的 sFLC 水平,通过与传统的 M 蛋白检测方法的比较来评价 sFLC 的临床意义。结果 (1)健康人 sFLC-κ、sFLC-λ的95%参考区间分别为(9～29)mg/L、(15～34)mg/L,sFLC-κ/λ比值的中位值为0.59,100%参考区间为0.27～2.49。(2)初治 MM 患者中,κ增高的 MM(κ-MM)患者的 sFLC-κ、sFLC-λ的95%参考区间分别为(53～14 100)mg/L、(0～97)mg/L,sFLC-κ/λ比值中位值为10.27;λ增高的MM(λ-MM)患者的sFLC-κ、sFLC-λ95%参考区间分别为(9～117)mg/L、(205～6875)mg/L,sFLCκ/λ比值中位值是0.005。MM患者 sFLC-κ、sFLC-λ的95%参考区间与健康人间无交叉重叠。96.4%(26/27)初治 MM 患者的sFLCκ/λ比值异常。(3)健康人 sFLC-κ、sFLC-λ均与年龄呈正相关(P 值分别为0.031、0.01),而sFLCκ/λ比值与年龄无相关性(P=0.861)。初治 MM 患者年龄与 sFLC-κ、sFLC-λ浓度及 sFLCκ/λ比值间均无相关性(P 分别为0.287、0.408、0.471)。(4)对于初治患者,检测κ克隆时比浊法与免疫固定法的敏感性和特异性分别是100% vs 73.7%和100% vs 44.4%;检测λ克隆时比浊法与 IFE 法的敏感性和特异性分别是100% vs 68.8%和100% vs 58.3%。对于治疗后达完全缓解的 MM 患者比浊法仍可以检测到单克隆 M 蛋白的存在。结论首次获得了一个中国人 sFLC-κ、sFLC-λ及 sFLCκ/λ的正常参考区间。自动免疫比浊法检测 sFLC 可以提高 MM 患者的初诊时的阳性率和疗效判断准确率。
文摘目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,SYFPEITHI和NetCTL方法预测分析其HLA-A*0201限制性CTL表位,运用NetCTL方法对HLA-A的其他等位基因和HLA-B限制性CTL表位进行预测分析.结果:HCCR蛋白的二级结构主要由α-螺旋结构组成,B细胞优势表位位于N端第41～53,216～228,310～325和355～360区段;预测得到5个HLA-A*0201限制性CTL优势表位分别为YLVFLLMYL(152～160),YLFPRQLLI(159～167),LLLHNVVLL(343～351),CLFLGIISI(138～146)和SIPPFA-NYL(145～153),HCCR蛋白HLA-A,B限制CTL表位主要位于胞外区.结论:应用多参数预测HCCR蛋白B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位,为进一步实验鉴定其表位进而制备单克隆抗体和基于HCCR抗原的肿瘤免疫学治疗奠定了基础.
文摘Background:B cells represent a crucial component of adaptive immunity that ensures long-term protection from infection by generating pathogen-specific immunoglobulins.Exercise alters B cell counts and immunoglobulin levels,but evidence-based conclusions on potential benefits for adaptive immunity are lacking.This systematic review assessed current literatures on the impact of acute exercise and exercise training on B cells,immunoglobulins,and markers of secretory immunity in human biofluids.Methods:According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)guidelines,MEDLINE,Web of Science,and Embase were searched on March 8,2023.Non-randomized controlled trials and crossover trials investigating the impact of acute exercise or exercise training on B cell counts and proportions,immunoglobulin levels,salivary flow rate,or secretory immunoglobulin A secretion rate were included.Quality and reporting of exercise training studies were assessed using the Tool for the Assessment of Study Quality and reporting in Exercise.Study characteristics,outcome measures,and statistically significant changes were summarized tabularly.Results:Of the 67 eligible studies,22 applied acute exercise and 45 applied exercise training.All included outcomes revealed significant alterations over time in acute exercise and exercise training context,but only a few investigations showed significant differences compared to control conditions.Secretory and plasma immunoglobulin A levels were most consistently increased in response to exercise training.Conclusion:B cell-related outcomes are altered by acute exercise and exercise training,but evidence-based conclusions cannot be drawn with high confidence due to the large heterogeneity in populations and exercise modalities.Well-designed trials with large sample sizes are needed to clarify how exercise shapes B cell-related immunity.
